Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05610917
Other study ID # ChengdeMU
Secondary ID
Status Not yet recruiting
Phase Early Phase 1
First received
Last updated
Start date January 1, 2023
Est. completion date January 1, 2026

Study information

Verified date November 2022
Source Chengde Medical University
Contact Li Duan, Dr.
Phone 86-13831425750
Email dfhedianren@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study intends to take patients with RGD as objects. Further construct a community-based rehabilitation management (CBRM) program with drug treatment, rehabilitation measures of education, psychology and exercise as its core content on the basis of evidence-based practice approach. Based on the cost-utility analysis of health economics, the health and economic benefits of the CBRM program will be evaluated, and a theoretical reference will be provided for community health institutions to carry out whole-course rehabilitation management practice and health policy formulation.


Description:

Based on the background of population aging, the prevalence of Late life depression tends to increase, and the recurrence rate after antidepressants treatment is still as high as 35%-57%, and the disease course tends to be chronic. Therefore, the formulation and implementation of prevention and control programs have become a significant part of the government's work plan. Physical frailty symptoms such as loss of daily activities and weakness are common in patients with remitted geriatric depression (RGD), and cognitive impairment is also considered to be an independent persistent symptom of RGD patients, which are related to the fluctuation and recurrence of depressive symptoms in elderly patients. Physical cognitive decline syndrome (PCDS) can comprehensively assess the physical frailty symptoms and the degree of cognitive impairment of the elderly, and effectively predict the course of the disease and the trend of healthy development. However, studies applied to the field of emotional disorder have not been retrieved. Therefore, this study intends to take patients with RGD as objects to investigate the prevalence of PCDS, build a risk prediction model and reveal it is warning mechanisms. That is, after determinning the basis of risk factors affecting the occurence of PCDS in RGD patients, we will carry out the formulation, implementation and evaluation of the follow-up CBRM program.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 120
Est. completion date January 1, 2026
Est. primary completion date January 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria: - aged 60 years old or above at the time of enrollment; - meet the diagnostic criteria for MDD without psychotic features according to DSM-5, and depressive symptoms have been improved and remained stable for at least 2 months after treatment with SSRIs; - the total score of HAMD-17 is less than 7 at the time of enrollment; - meet the diagnostic criteria for physio-cognitive decline: 1) the total score of ADL and IADL was less than 26; 2)cognitve decline: first, subjects with severe impairment of cognitive function will be excluded (years of education = 6, MMSE scores <24;years of education <6 years, MMSE total score <14). After completing a neuropsychological task, cogintive declined will be confirmed when any aspects of cognitve function is 1.5 standard deviations lower than that of normal elderly; 3) the grip strength is weakened, and the domaint hand grip strength is < 28kg for males or <18kg for females; 4)slow step speed, that is, in a space of length >10 meters, the subjects walks 6 meters from the starting point at a normal and uniform pace, and the pace is <1m/s. - comprehension, reading and writing skills to complete the measurements or complete them with assistance of the researchers with obstacles; - voluntary participation and signed informed consent. Exclusion Criteria: - meet the diagnostic of schizophrenia, bipolar disorder, dementia; - comorbidity of physical diseases, such ascardiovascular and cerebrovascular diseases, rheumatoid arthritis, stroke and malignant tumors; - history of alcohol or drug dependence; - severe deformity of spine and limbs; - complete or partial dependence on caregivers for daily life, such as long-term bedridden, wheelchair assisted; - have received physical therapy or psychological treatment in the past three months; - currently participating in other clinical research.

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
CBRM (community-based rehabilitation management)
The case group patients will undergo drug treatment (Selective Serotonin Reuptake Inhibitors), health education, cognitive-motor dual task training, cognitive-training.
TAR(treatment as routine)
Patients in control group will be treated rountinely which includes drug treatment (SSRIs) and traditional health education.

Locations

Country Name City State
China Chengde Medical University Chengde Hebei

Sponsors (1)

Lead Sponsor Collaborator
Duan Li

Country where clinical trial is conducted

China, 

References & Publications (6)

Chen LK, Arai H. Physio-cognitive decline as the accelerated aging phenotype. Arch Gerontol Geriatr. 2020 May - Jun;88:104051. doi: 10.1016/j.archger.2020.104051. Epub 2020 Apr 4. — View Citation

Chen LK, Hwang AC, Lee WJ, Peng LN, Lin MH, Neil DL, Shih SF, Loh CH, Chiou ST; Taiwan Health Promotion Intervention Study for Elders research group. Efficacy of multidomain interventions to improve physical frailty, depression and cognition: data from cl — View Citation

Liang CK, Lee WJ, Hwang AC, Lin CS, Chou MY, Peng LN, Lin MH, Chen LK. Efficacy of Multidomain Intervention Against Physio-cognitive Decline Syndrome: A Cluster-randomized Trial. Arch Gerontol Geriatr. 2021 Jul-Aug;95:104392. doi: 10.1016/j.archger.2021.1 — View Citation

Liu LK, Chou KH, Hsu CH, Peng LN, Lee WJ, Chen WT, Lin CP, Chung CP, Wang PN, Chen LK. Cerebellar-limbic neurocircuit is the novel biosignature of physio-cognitive decline syndrome. Aging (Albany NY). 2020 Nov 25;12(24):25319-25336. doi: 10.18632/aging.10 — View Citation

Merchant RA, Chan YH, Hui RJY, Tsoi CT, Kwek SC, Tan WM, Lim JY, Sandrasageran S, Wong BLL, Chen MZ, Ng SE, Morley JE. Motoric cognitive risk syndrome, physio-cognitive decline syndrome, cognitive frailty and reversibility with dual-task exercise. Exp Ger — View Citation

Ngandu T, Lehtisalo J, Solomon A, Levälahti E, Ahtiluoto S, Antikainen R, Bäckman L, Hänninen T, Jula A, Laatikainen T, Lindström J, Mangialasche F, Paajanen T, Pajala S, Peltonen M, Rauramaa R, Stigsdotter-Neely A, Strandberg T, Tuomilehto J, Soininen H, — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary depressive symptoms The Hamilton Depressive Scale (HAMD-17) which consists of 17 items will be employed to screen for depressive symptoms and evaluate the mental status and severity of depressive symptoms. Scores were calculated by totaling the responses, which can be divided into four types (Health): normal/not depressed (0-7 points), mild/subthreshold (8-13), moderate/mild (14-18), severe/moderate (19-22), and severe/very severe (>23). This variable will be measured at 0 (baseline) and after 3, 6 months post-intervention.
Primary cognitive and intellectual function Mini-mental State Examination (MMSE), as a simple screening tool for cognitive and intellectual function decline in the elderly with a total score of 30. The results of this test is closely related to the level of education, and the normal cutoff is defined as, illiterates >17 points, primary schools >20 points, and middle schools and above >24 points. This variable will be measured at 0 (baseline) and after 3, 6 months post-intervention.
Primary changes of the handgrip strength The grip strength of a man's dominant hand < 28kg or a woman < 18kg is considered to have weak grip strength. The grip strength increased compared with the baseline period, that is, the subjects' physiological function tended to recover; Instead, physiological function tends to decline. This variable will be measured at 0 (baseline) and after 3, 6 months post-intervention.
Primary changes of the gait speed The time it takes for the subject to walk 6 meters at normal pace from the starting point without slowing down, with a threshold for gait deceleration set to < 1m/s. The gait speed increased compared with the baseline period, that is, the subjects' physiological function tended to recover; Instead, physiological function tends to decline. This variable will be measured at 0 (baseline) and after 3, 6 months post-intervention.
Secondary quality of life of the elderly The WHO Quality of Life Scale (WHOQOL-BREF Chinese version) includes four dimensions, such as physiological, psychological, social relations and environment, covering 26 items related to quality of life. This scale is widely used in patients with cancer, chronic diseases and the elderly. Each item is scored according to Likert 1-5. The higher the total score, the better the quality of life. This variable will be measured at 0 (baseline) and after 3, 6 months post-intervention.
Secondary sleep quality The Pittsburgh Sleep Quality Index (PSQI) will be used to measure the subjects' sleep treatment. The total score range is 0-21 points. It is generally believed that the total score of PSQI =7 indicates that the sleep quality is fair, while the total score of > 7 indicates poor sleep quality, and the higher the total score of PSQI scale, the worse the sleep quality of the subjects. This variable will be measured at 0 (baseline) and after 3, 6 months post-intervention.
Secondary the balance ability of the elderly The Short Physical Performance Battery test (SPPB) will be used to assess the balance ability of the elderly, including: (1) Sit-stand test for 5 times. The shorter the time, the better the balance ability. (2) Timing test of 2.44m short distance walking. The shorter the time, the better the balance ability. (3) Balance function test, the longer the time, the better the balance ability. This variable will be measured at 0 (baseline) and after 3, 6 months post-intervention.
Secondary activity of daily living Activity of Daily Living (ADL) whose total score is ranging from 14 to 56. Total score =26, basically normal; > 26 indicates different degree of functional decline; Score of 2 or more individual scores > 3 points, significant dysfunction. This variable will be measured at 0 (baseline) and after 3, 6 months post-intervention.
Secondary the word memory function Chinese Version Verbal Learning Test (CVVLT) will be used to evaluate the word memory function of the elderly. Researchers repeated 9 words at a rate of one word per second for four times in a fixed sequence. The elderly will be asked to recall the words 30 seconds later and again 10 minutes later. In this study, only the results of the delayed free memory test at the 10th minute will be included in the later statistics. The more vocabularies remembered, the better the cognitive function. This variable will be measured at 0 (baseline) and after 3, 6 months post-intervention.
Secondary language functions Boston Naming Test (BNT-30) will be used to evaluate language functions of the elderly. During the test, if the subject could make a spontaneous naming error within 20 seconds, the semantic cue will be used to prompt the subject; if the subject could not answer within 20 seconds, the subject will be given a recognition choice including three choices. The evaluation indexes include spontaneous correct naming number, prompt correct naming percentage and selection of correct naming percentage. The higher the score, the better the cognitive function. This variable will be measured at 0 (baseline) and after 3, 6 months post-intervention.
Secondary verbal functions Verbal Fluency Test (VFT) will be used to assess the verbal functions of the elderly. Subjects are required to say as many animal names as possible within one minute. The test involves multiple cognitive functions such as memory, language and execution, which is the most important tool for testing subjects' language fluency. The more words they can say, the better their cognitive function. This variable will be measured at 0 (baseline) and after 3, 6 months post-intervention.
Secondary visuospatial structure ability and visual memory of the elderly Rey-Osterrieth Complex Figure Test (ROCFT) will be used to asses the visuospatial structure ability and visual memory of the elderly. During the test, the elderly will be asked to copy complex images. Researchers record the copying time and remove the cards immediately after the copying completed. After 3 minutes and 30 minutes, the subjects will be asked to re-draw according to the recall, and the researchers record the duration of the instantaneous recall. Each drawing should take no more than 10 minutes. Reference standards will used to score the images of copying, instantaneous meeting and delayed recall respectively, with a total score of 36 points. This variable will be measured at 0 (baseline) and after 3, 6 months post-intervention.
Secondary working memory portion of the executive function Digital Backward (DB) will be used to evaluate the working memory portion of the executive function. The elderly will be asked to read a sequence of numbers at a rate of one number per second and asked to immediately repeat the sequence in reverse order. The number of numbers in the last sequence that the subject can recite correctly is the score of the DB test. This variable will be measured at 0 (baseline) and after 3, 6 months post-intervention.
Secondary the executive ability and the visuospatial ability Clock Drawing Test (CDT) will be used to evaluate the executive ability and the visuospatial ability. Subjects will be asked to draw the face of a clock and write all the numbers. The hour and minute hands point to 11:10. The clock face is complete (0-2 points), the number is complete and sequence (0-4 points), and the pointer is complete and position (0-4 points). The higher the total score is, the better the cognitive function is. This variable will be measured at 0 (baseline) and after 3, 6 months post-intervention.
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05054660 - Applying a Chatbot to Geriatric Patients in Psychiatric Clinics: A Pilot Study N/A
Completed NCT04504175 - Ketamine for Older Adults Pilot Phase 4
Recruiting NCT05588102 - Electronic Training of Elderly Depression With Cognitive Impairment N/A
Completed NCT02960763 - Optimizing Outcomes of Treatment-Resistant Depression in Older Adults Phase 4
Active, not recruiting NCT05531591 - RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT) Phase 4